Results 51 to 60 of about 9,329 (213)

Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1371-1381, May 2026.
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence‐based treatment decisions.
Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Janine Scholefield, Collen Masimirembwa   +5 more
wiley   +1 more source

Rapid in vitro evolution of flucytosine resistance in Candida auris

mSphere
The pan-antifungal-resistant pathogen Candida auris has been causing high-mortality infection outbreaks in hospitals and healthcare settings. The prodrug 5-fluorocytosine (5FC) is one of four chemical entities, but its clinical use as an antifungal drug ...
Trinh Phan-Canh, Duc-Minh Nguyen-Le, Phuc-Loi Luu, Narakorn Khunweeraphong, Karl Kuchler   +4 more
doaj   +1 more source

Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China

Brazilian Journal of Infectious Diseases, 2012
Cryptococcus spp. are common causes of mycoses in immunocompromised patients. To determine the drug susceptibilities of clinical Cryptococcus spp. isolates, the characteristics of 61 clinical Cryptococcus spp.
Meng Li, Yong Liao, Min Chen, Weihua Pan, Lixing Weng   +4 more
doaj   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1382-1390, May 2026.
Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the ...
Janine Scholefield, Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Collen Masimirembwa   +5 more
wiley   +1 more source

The Effect of Cilofungin (LY 121019) in Combination with Amphotericin B or Flucytosine Against Candida Species [PDF]

, 1989
Cilofungin was combined with amphotericin B or flucytosine to determine if synergistic inhibition or killing occurred against 50 strains of various Candida species.
Bradley, Suzanne F., Carol A. Kauffman, A.N. Bulo, Suzanne F. Bradley, Bulo, A. N., Kauffman, Carol A.   +5 more
core   +1 more source

Enhancement of antifungal activity and transdermal delivery of 5-flucytosine via tailored spanlastic nanovesicles: statistical optimization, in-vitro characterization, and in-vivo biodistribution study

Frontiers in Pharmacology, 2023
Aim and background: This current study aimed to load 5-flucytosine (5-FCY) into spanlastic nanovesicles (SPLNs) to make the drug more efficient as an antifungal and also to load the 5-FCY into a hydrogel that would allow for enhanced transdermal ...
Awaji Y. Safhi, Nimbagal Raghavendra Naveen, Krishna Jayanth Rolla, Penmetsa Durga Bhavani, Mallesh Kurakula, Khaled M. Hosny, Walaa A. Abualsunun, Mohammed Alissa, Abdullah Alsalhi, Amerh Aiad Alahmadi, Khalid Zoghebi, Abdulrahman Sindam Halwaani, Rasha Ibrahim K   +12 more
doaj   +1 more source

Probiotic‐based strategies in vulvovaginal candidiasis management: A comprehensive review of mechanisms and future directions

Interdisciplinary Medicine, Volume 4, Issue 3, May 2026.
This review focuses on vulvovaginal candidiasis (VVC), examining its epidemiology, the pathogenesis of Candida albicans, and its relationships with vaginal microbiota. It comprehensively reviews probiotic‐based management strategies and their mechanisms of action, and concludes by discussing current limitations, challenges and future research ...
Tong Chen, Yuwei Wu, Ya Chen, Ying Li, Hui Zhao, Lei Wu, He Gao, Tong Jiang, Xiaohong Wang, Moutong Chen, Jumei Zhang, Xinqiang Xie, Tingting Liang, Qingping Wu   +13 more
wiley   +1 more source

Malabsorption of Flucytosine in a Pediatric Patient with Shwachman Syndrome

, 1989
The malabsorption of drugs from the gastrointestinal tract in patients with pancreatic insufficiency is not well documented in the literature. We describe a case of flucytosine malabsorption in a pediatric patient with Shwachman syndrome, a rare disease
Karen J. Harper, William T. Sawyer
core   +1 more source

In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. [PDF]

, 2008
Contains fulltext : 69799.pdf (Publisher’s version ) (Open Access)The antifungal agent flucytosine was found to be active in vitro against Aspergillus fumigatus isolates when the MIC was determined at pH 5.0 instead of pH 7.0.
Meis, J.F.G.M., Janssen, W.H.P., Mouton †, J.W., Mouton, J.W., Dorsthorst, D.T.A. te, Verweij, P.E.   +5 more
core   +1 more source

Comparative Antifungal Activity of Cilofungin (LY121019) against Candida Species, Including Evaluation of Susceptibility Testing Method

Canadian Journal of Infectious Diseases, 1992
The in vitro activity of cilofungin against 100 Candida species was compared with 5-flucytosine. amphotericin B and ketoconazole by two laboratories independently and in a blinded fashion using a macrotitre dilution broth method in saam-f medium ...
Abdul H Chagla, John H Hii, Daryl J Hoban, Andrew E Simor, Santiago Ferro, Evelyn Witwicki, Ruby Poon, Donald E Low   +7 more
doaj   +1 more source